Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis by Denderen, J.C. van et al.
EXTENDED REPORT
Double blind, randomised, placebo controlled study
of leflunomide in the treatment of active ankylosing
spondylitis
J C van Denderen, M van der Paardt, M T Nurmohamed, Y M M A de Ryck,
B A C Dijkmans, I E van der Horst-Bruinsma
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr I E van der Horst-
Bruinsma, VU University
Medical Centre,
Department of
Rheumatology 4A-42, PO
Box 7057, 1007 MB
Amsterdam, Netherlands;
IE.vanderHorst@vumc.nl
Accepted 14 May 2005
Published Online First
18 May 2005
. . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2005;64:1761–1764. doi: 10.1136/ard.2005.036491
Objective: To assess the efficacy and safety of leflunomide in active ankylosing spondylitis (AS) compared
with placebo in a 24 week pilot study.
Methods: In a single centre randomised, double blind, placebo controlled study, 45 patients with active AS
were randomised to either leflunomide 20 mg daily (n =30) or placebo (n=15). Active disease was defined as
a score of >4 on the Bath ankylosing spondylitis disease activity index (0–10), and pain of >4 on a visual
analogue scale (0–10). The primary efficacy variable at week 24 was the 20% response rate, as recommended
by the Assessments in Ankylosing Spondylitis (ASAS) working group. Secondary outcome variables included
general wellbeing, metrology index, swollen joint count, erythrocyte sedimentation rate, and C reactive protein.
Results: In all, 13 women and 32 men were studied. Demographic and disease indices were comparable
between the two treatment groups at baseline. The rate of ASAS 20% responders was not significantly
different: 27% in the leflunomide treated patients and 20% in the placebo group (95% confidence interval,
232% to 19%). No significant differences were found between the treatment groups in mean changes of
the secondary outcome variables. Eleven patients were withdrawn prematurely from the study because of
adverse events (7), lack of efficacy (3), and non-compliance (1). Most frequently adverse events were
gastrointestinal side effects and skin disorders.
Conclusions: In this placebo controlled study, leflunomide treatment did not result in a significant
improvement of the ASAS 20% response in active ankylosing spondylitis. No unexpected or severe
adverse events occurred.
A
nkylosing spondylitis (AS) is an autoimmune disease
characterised by chronic inflammation of the sacroiliac
and spinal joints and entheses. The disease occurs
mainly in young adults and can lead to stiffness and
deformity of the vertebral column, with invalidating defor-
mities. AS is often accompanied by extraspinal manifesta-
tions as arthritis of the peripheral joints, and involvement of
the eye (acute anterior uveitis), heart, and lungs.
Treatment was, until recently, mainly based on non
steroidal anti-inflammatory drugs (NSAIDs) and physical
therapy.1 The disease modifying antirheumatic drugs
(DMARDs), for example sulfasalazine and methotrexate,
seem to be less beneficial in AS than in other rheumatic
diseases such as rheumatoid arthritis.2 Recent studies have
shown that the tumour necrosis factor a (TNFa) blocking
agents infliximab and etanercept are very effective in a large
proportion of patients with AS.3 4 These powerful drugs,
however, are costly and are sometimes accompanied by
severe adverse effects such as opportunistic infections.
Moreover, these agents fail to reach efficacy in approximately
30% of the patients.5 For these reasons we investigated the
efficacy and safety of another DMARD, leflunomide—a drug
proven to be effective in rheumatoid arthritis.6–9 In addition,
leflunomide shows beneficial effects in patients with
psoriatic arthritis which, like AS, belongs to the group of
spondyloarthritides.10–13 In the present study the efficacy and
safety of leflunomide was investigated in patients with active
AS in a randomised, double blind, placebo controlled trial.
METHODS
Consecutive patients with AS were recruited from the
outpatient rheumatology clinic of the Jan van Breemen
Institute (referral centre) and the surrounding hospitals in
Amsterdam. The study was carried out in the period from
March 2002 to September 2003. The study group comprised
45 patients aged 18 to 70 years with active definite AS,
diagnosed according to the modified New York criteria.14
Active disease was defined as: at least a 4 point score on the
Bath ankylosing spondylitis disease activity index (BASDAI;
scale 0–10) and a pain score of at least 4 on a visual analogue
scale (VAS; scale 0–10) at screening.
NSAIDs and corticosteroids up to a maximum daily dose of
15 mg prednisone were allowed on an unchanged regimen
for at least 30 days before the study drug administration and
throughout the study. The use of DMARDs (particularly
sulfasalazine, methotrexate, and TNF blocking agents)
during the study and within the 30 days before the study
was not permitted.
Both men and women were required to practice contra-
ception. In female patients of childbearing potential a urine
pregnancy test was done at baseline and any pregnant
women were excluded.
Other exclusion criteria were: impaired hepatic enzyme
tests (alanine and aspartate transaminases more than twice
the upper laboratory limit of normal), impaired renal function
(serum creatinine .110 mmol/l), untreated hypertension,
Abbreviations: AS, ankylosing spondylitis; ASAS, Assessments in
Ankylosing Spondylitis; BASDAI, Bath ankylosing spondylitis disease
activity index; BASG, Bath ankylosing spondylitis global score; BASMI,
Bath ankylosing spondylitis metrology index; DMARD, disease
modifying antirheumatic drug; MMP, matrix metalloproteinase; NSAID,
non-steroidal anti-inflammatory drug; SJC, swollen joint count; VAS,
visual analogue scale
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malignancy, diagnosis of other inflammatory joint diseases,
impaired bone marrow function, recent serious infections, and
any clinically relevant cardiovascular, hepatic, neurological,
endocrine. or other major systemic diseases.
Design
Forty five eligible patients were randomised at baseline
(within four weeks after screening) to receive either
leflunomide (n=30) or matching placebo (n=15) for 24
weeks. The dosage schedule included a loading dose of
100 mg (given on day 1, 8, and 15) and leflunomide 20 mg
on the other days during the first three weeks, followed by a
maintenance dose of 20 mg daily. We often apply this slightly
modified dosing schedule, as we have the impression that the
rate of gastrointestinal complaints is less than with the
standard schedule. Compliance was assessed by tablet counts
of returned study preparations and was calculated on the
basis of the number of days in the study.
Efficacy and safety indices (vital signs and adverse events)
were assessed at baseline, week 4, week 12, and week 24. The
following efficacy variables were used: BASDAI,15 pain
assessed on a VAS (0–10), BASFI,16 Bath ankylosing
spondylitis global score (BASG),17 Bath ankylosing spondy-
litis metrology index (BASMI),18 44 swollen joint count
(SJC), general wellbeing on a VAS (0–10) according to the
physician, erythrocyte sedimentation rate (ESR), and C
reactive protein.
Blood tests (haematology and blood chemistry) were
monitored every two weeks during the first six weeks and
at regular intervals later during the study period.
Statistics
Based on an assumed 50% response rate for leflunomide and
20% for placebo, adjusting for a non-evaluable rate of 25%, 61
patients per treatment would have been needed to reach a
level of significance of 0.05 with a power of 80%. Underlining
the explorative character of this trial, and because of obvious
feasibility issues in this single centre study, it was decided to
randomise 45 patients. Expecting a higher dropout rate in the
leflunomide group, a randomisation ratio was defined with a
2:1 balance (30 leflunomide patients and 15 placebo patients)
so as to ensure a minimum collection of efficacy and safety
data in a new indication for leflunomide. Altogether, the
power of the study was reduced to 65%, which reasonably
can be said to show at most an effect trend.
The primary efficacy variable was the 20% response rate, as
recommended by the Assessments in Ankylosing Spondylitis
(ASAS) working group.19 Each patient was classified as a
treatment responder or non-responder at the end point (week
24 or last available observation under treatment). The ASAS
20% response was defined as improvement of >20% and
absolute improvement of >1 unit (on a scale of 0 to 10) in at
least three of the following four domains and absence of
deterioration (change for the worse of >20% and net
worsening of >1 unit) in the remaining domain: patient
global assessment, pain (VAS), BASFI, and inflammation
(the mean of the two morning stiffness related BASDAI VAS
scores).
The responder rates in the two treatment groups were
compared using the binomial test for two samples, and the
95% confidence intervals were calculated.
Subgroup analyses were done in patients with an ESR of
.30 mm/h or a C reactive protein of .10 mg/l, or both, at
baseline, and in patients with peripheral arthritis (SJC .1 at
baseline).
The secondary efficacy variables at end point were
compared with the assessments at baseline and 95%
confidence intervals for the differences between leflunomide
and placebo for the mean changes from baseline were
calculated. Student’s t test was used for variables with a
normal distribution and the Mann–Whitney U test for
variables with a non-normal distribution. A two sided p
value of less than 0.05 was considered significant.
The primary and secondary efficacy analyses and safety
analysis were carried out on an intention to treat basis.
The efficacy analysis was also done for the per-protocol
(PP) population. We defined the PP population as all patients
treated with a minimum drug exposure of eight weeks, and
excluding one patient in whom the prednisone dose was
increased. The PP population (36 patients) was identified
before unblinding the treatment allocation.
The study was approved by the local ethics review board,
and written informed consent was obtained from all patients.
RESULTS
Baseline characteristics
The demographic data of the patients and disease character-
istics at baseline are summarised in table 1. The variables
were comparable and not statistically different between the
two treatment groups. Fourteen patients had a history of
uveitis (eight leflunomide and six placebo). Two patients in
the leflunomide group and one in the placebo group had
inactive inflammatory bowel disease and one patient in both
groups had psoriasis. NSAIDs were used by 93% of the
leflunomide and 87% of the placebo treated patients.
Corticosteroids were used by one patient. None of the
patients had ever used a TNF blocking agent.
Primary efficacy variable
The number of responders according to the ASAS 20%
definition was 11: 8 (27%) in the leflunomide group and 3
(20%) in the placebo group (95% confidence interval (CI) for
difference, 232% to 19%).
In the subgroup with an ESR of >30 mm/h, or a C reactive
protein of >10 mg/l, or both, at baseline (n=26), the
response rate was 32% and 29% for the leflunomide and
the placebo group, respectively (242% to 36%).
In the subgroup of patients with peripheral arthritis (SJS
>1 at baseline), which included only four patients, the
response rate was 50% in the leflunomide and 100% in the
placebo group (219% to 100%).
In the per-protocol population the response rate was 6/24
(25%) in the patients treated with leflunomide and 2/12
(17%) in the placebo treated patients (236% to 19%).
Secondary efficacy variables
The mean secondary efficacy variables at baseline and the
mean changes after 24 weeks did not show any significant
differences of global disease activity (BASG), disease activity
index (BASDAI), functional index (BASFI), pain, metrology
Table 1 Demographic and mean (or median) baseline
characteristics (and ranges) of 45 patients with active
ankylosing spondylitis
Characteristic Placebo (n = 15)
Leflunomide
(n = 30)
Male sex (%) 10 (67) 22 (73)
% HLA-B27 positive 100 (14/14) 81 (21/26)
Age (years) 39 (25 to 58) 42 (22 to 66)
Median disease duration
(years) 5.7 (0.3 to 14.1) 9.4 (0.3 to 38.6)
Peripheral arthritis (%)* 2(13) 2 (7)
BASDAI (0–10) 5.9 (2.9 to 9.7) 6.4 (2.7 to 9.5)
ESR (mm/h) 18 (2 to 54) 22 (2 to 66)
*Number of patients with at least one swollen joint.
BASDAI, Bath ankylosing spondylitis disease activity index; ESR,
erythrocyte sedimentation rate.
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index (BASMI), swollen joint count or C reactive protein
between the treatment groups (table 2). The mean change in
ESR was the only variable that differed significantly between
the treatment groups in favour of the placebo group. This
observation was the result of a skewed distribution of the
ESR, because the differences between the median changes
were much smaller.
Adverse events and dropouts
Adverse events were seen in 24 leflunomide cases (80%) and
10 placebo cases (67%). The adverse events were classified as
possibly drug related in 18 (60%) and six (40%) of the
leflunomide and placebo treated patients, respectively. No
serious adverse events were seen. Most frequent or clinically
relevant adverse events were: gastrointestinal disorders (57%
in the leflunomide and 33% in the placebo treated patients,
respectively); upper respiratory tract infections (17% in the
leflunomide and 27% in the placebo treated patients);
dermatitis and prurigo (13% in both groups); fatigue (in
13% of the placebo treated patients); deep venous thrombosis
(in one placebo patient). In the leflunomide group, a rise in
liver enzymes to three times the upper normal limit was
observed in one patient with borderline liver enzyme tests at
baseline. No clinically relevant changes were found in the
other laboratory variables. No changes were seen in the mean
blood pressures. Antihypertensive treatment had to be
increased in one patient treated with leflunomide.
Eleven patients were withdrawn prematurely from the
study (fig 1), for the following reasons: adverse events (five
leflunomide patients, two placebo patients); lack of efficacy
(three leflunomide patients); non-compliance (one placebo
patient). Four of these dropouts were responders (three
leflunomide patients and one placebo patient). Adverse
events leading to withdrawal were gastrointestinal disorders
(4), malaise (1), exacerbation of pain (1), headache (1), and
erectile dysfunction (1).
Compliance
On the basis of the number of days in the study (leflunomide,
mean 134 days; placebo, mean 142 days) and the number of
returned tablets, the calculated compliance was 96% in the
leflunomide group and 93% in the placebo group.
DISCUSSION
Leflunomide did not result in significant clinical improve-
ment in active ankylosing spondylitis in this placebo
controlled study. The number of AS patients who fulfilled
the ASAS 20% response rate was higher in the leflunomide
group than in the placebo group, but the difference did not
reach statistical significance. The changes in the individual
secondary disease outcome indices were comparable.
Importantly, no serious or unexpected adverse events were
encountered.
Only one other study has investigated the efficacy of
leflunomide in AS; this was an open label non-comparative
trial of 20 AS patients who were treated for 24 weeks.20 Ten
patients were prematurely withdrawn because of lack of
efficacy, side effects, or non-compliance. In line with our
results, leflunomide seemed to be ineffective. The only
significant improvement observed was in a subgroup of 10
patients suffering from peripheral arthritis. In our study, only
four patients had peripheral arthritis in at least one joint and
therefore we could not draw any conclusions about the
efficacy of leflunomide in this subgroup.
The efficacy of leflunomide in AS in our study appears
disappointing but it is consistent with the experience with
other DMARDs in AS. Most studies with DMARDs in AS,
particularly sulfasalazine, show improvement of the periph-
eral arthritis and ESR, but no significant improvement in the
axial complaints.2 21 Mesalazine, which is very effective in
inflammatory bowel disease, was not shown to be effective in
AS.22 Limited data are available of methotrexate in AS, but a
recent small placebo controlled trial (in which a lower dose
was used than in most studies in rheumatoid arthritis)
showed favourable results.23 The large number of patients
Table 2 Mean efficacy variables at baseline and the mean change after 24 weeks with the 95% confidence interval for the
difference in change between the treatment groups
Variable
Placebo (n = 15) Leflunomide (n = 30)
95% CI* p ValueBaseline Mean change Baseline Mean change
BASG last week (0–10) 5.8 20.6 6.9 21.3 (20.9 to 2.4) 0.32
BASG last six months 6.7 21.5 7.4 20.7 (22.2 to 0.6) 0.26
Pain (0–10) 6.2 20.5 6.8 21.4 (20.9 to 2.8) 0.28
BASFI (0–10) 5.4 20.4 5.2 0.0 (21.3 to 0.5) 0.35
BASDAI (0–10) 5.9 20.3 6.4 21.1 (20.5 to 2.0) 0.20
BASMI (0–10) 3.3 0.3 4.2 0.0 (20.1 to 0.8) 0.10
SJC (0–44) 0.4 20.2 0.1 0.2 (20.9 to 0.1) 0.09
Global physician (0–10) 5.1 20.7 5.5 20.5 (21.1 to 0.8) 0.70
ESR (mm/h) 18.1 21.9 22.1 8.4 (217.8 to 22.9) 0.002
C reactive protein (mg/l) 21.4 26.1 27.0 6.5 (230.9 to 5.8) 0.09
*95% confidence interval for difference of mean change between placebo and leflunomide.
General wellbeing of the patient according to physician.
BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASG, Bath ankylosing spondylitis global score;
BASMI, Bath ankylosing spondylitis metrology index; ESR, erythrocyte sedimentation rate; SJC, swollen joint count.
22 Completers
(73.3%)
30 Leflunomide
12 Completers
(80%)
3 Withdrawals
(20%)
15 Placebo
5 (16.7%)
because of AE
2 (13.3%)
because of AE
45 Randomised
52 Screened
11 Withdrawals
(24.4%)
8 Withdrawals
(26.7%)
Figure 1 Trial profile. Five screened patients are not included because
they did not meet the criteria for disease activity, and two patients
because they wanted to have a child. AE, adverse events.
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with peripheral arthritis in that study (65% of the 17
recruited patients) was striking.
In rheumatoid arthritis leflunomide reduces the numbers
of macrophages and T cells infiltrating the synovium, and the
expression of adhesion molecules, proinflammatory cyto-
kines, and mediators of joint destruction such as matrix
metalloproteinases (MMPs).24 Whereas the molecular path-
ways have been thoroughly analysed in rheumatoid arthritis,
the mechanisms of joint inflammation and destruction are
less well understood in AS. In sacroiliac biopsies from 32
patients with spondyloarthritis, T cells and macrophages
were the predominant cells, suggesting an important role
for these cell types in the pathogenesis.25 Moreover, TNFa
blocking treatment in AS downregulates both cytokines
secreted by T cells and MMPs in the synovium in spondy-
loarthritis.26 27 Therefore an effect of leflunomide on AS could
be expected. It is interesting that significantly higher serum
MMP-3 concentrations are encountered in AS patients with
peripheral joint disease than in those with only axial
symptoms.27 This latter finding could be the pathophysiolo-
gical explanation for a possible effect of leflunomide in cases
of AS with peripheral joint disease.
It is clear that leflunomide is not effective when compared
with the very efficacious TNFa blocking agents, although
direct comparative trials have not been conducted. An
interesting observation from a trial of anti-TNFa treatment
in AS was that patients with a raised C reactive protein had
greater benefit from the treatment than those with lower
levels.3 However, in our study no difference in responder rate
between the treatment groups was seen in the subgroup with
an ESR of >30 mm/hour or a C reactive protein of >10 mg/l,
or both, at baseline.
Conclusion
This is the first double blind, placebo controlled study of
leflunomide in active AS. Unfortunately, it was not possible
to show that it had significantly better efficacy than placebo.
Whether or not this drug is beneficial for AS patients with
peripheral arthritis remains to be established, as in our study
the number of such patients was too small to allow us to
draw meaningful conclusions. This might be an interesting
subject for future research.
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